P. Anderson

发表

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.

B. E. Evans, D. Veber, K. Rittle, 1988, Journal of medicinal chemistry.

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin.

W. F. Hoffman, P. Anderson, A. Alberts, 1986, Journal of medicinal chemistry.

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.

B. E. Evans, D. Veber, K. Rittle, 1988, Journal of medicinal chemistry.

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

P. Anderson, W. Schleif, E. Emini, 1995, Antimicrobial agents and chemotherapy.

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 3. 7-(3,5-Disubstituted [1,1'-biphenyl]-2-yl)-3,5-dihydroxy-6-heptenoic acids and their lactone derivatives.

W. F. Hoffman, P. Anderson, J. Hirshfield, 1986, Journal of Medicinal Chemistry.

X-Ray Crystal Structure of the HIV Protease Complex with L-700,417, an Inhibitor with Pseudo C2 Symmetry

M. Katharine Holloway, Roger F. Bone, P. Anderson, 1991 .

Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.

B. E. Evans, D. Veber, K. Rittle, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Martinelline and Martinellic Acid, Novel G-Protein Linked Receptor Antagonists from the Tropical Plant Martinella iquitosensis (Bignoniaceae)

Michael J. Salvatore, P. Anderson, S. Varga, 1995 .

Martinelline and Martinellic Acid, Novel G-Protein Linked Receptor Antagonists from the Tropical Plant Martinella iquitosensis ( Bignoniaceae).

P. Anderson, S. Varga, S. Pitzenberger, 1995 .

Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran.

P. Anderson, J. Huff, P. Fitzgerald, 1994, Journal of medicinal chemistry.

Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.

P. Anderson, V. J. Lotti, J. Huff, 1983, Journal of medicinal chemistry.

Conformational alterations detected by circular dichroism induced in the normal ras p21 protein by activating point mutations at position 12, 59, or 61.

L. Serrano, P. Anderson, J. Lacal, 1988, European journal of biochemistry.

Ras p21 proteins with high or low GTPase activity can efficiently transform NIH 3T3 cells

S. Srivastava, P. Anderson, S. Aaronson, 1986, Cell.

Quantitative structure-activity relationships involving the inhibition of glycolic acid oxidase by derivatives of glycolic and glyoxylic acids.

P. Anderson, E. Eichler, W. Randall, 1979, Journal of medicinal chemistry.

Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.

B. E. Evans, K. Rittle, M. Bock, 1989, Journal of medicinal chemistry.

Reflections on Medicinal Chemistry at Merck, West Point

P. Anderson, 2012 .

Design of cholecystokinin peptidomimetics

B. E. Evans, D. Veber, K. Rittle, 1992 .

Topically active carbonic anhydrase inhibitors. 2. Benzo[b]thiophenesulfonamide derivatives with ocular hypotensive activity.

K. Shepard, P. Anderson, J. Baldwin, 1989, Journal of medicinal chemistry.

Deletion mutants of Harvey ras p21 protein reveal the absolute requirement of at least two distant regions for GTP‐binding and transforming activities.

P. Anderson, S. Aaronson, J. Lacal, 1986, The EMBO journal.

Rapid stimulation of diacylglycerol production in Xenopus oocytes by microinjection of H-ras p21.

P. Anderson, S. Aaronson, J. Moscat, 1988, Science.

Cyclopsychotride A, a biologically active, 31-residue cyclic peptide isolated from Psychotria longipes.

P. Anderson, M. Sardana, M. Bogusky, 1994, Journal of natural products.

Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802.

J. Wityak, P. Anderson, S. Mousa, 1998, Journal of cardiovascular pharmacology.

X-Ray Crystal Structure of the HIV Protease Complex with L-700,417 (I), an Inhibitor with Pseudo C2 Symmetry.

P. Anderson, M. Holloway, J. Vacca, 1992 .

Effects of a potent carbonic anhydrase inhibitor on bone resorption in organ culture.

K. Shepard, P. Anderson, G. Rodan, 1988, Endocrinology.

Nonpeptide glycoprotein IIb/IIIa inhibitors. 13. design and synthesis of an orally active pyrazolopiperazinone nonpeptide fibrinogen receptor antagonist

P. Anderson, J. Baldwin, R. Gould, 1997 .

Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.

J. Wityak, P. Anderson, S. Mousa, 1999, Journal of medicinal chemistry.

1-(((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido) bicyclo(2.2.1)heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl) piperazine (L-368,899): An Orally Bioavailable, Non-Peptide Oxytocin Antagonist with Potential Utility for Managing Preterm Labor.

B. E. Evans, M. Bock, R. Freidinger, 1994 .

1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.

B. E. Evans, M. Bock, P. Anderson, 1994, Journal of medicinal chemistry.

SYNTHESIS OF 4-SUBSTITUTED 2H-NAPHTH(1,2-B)-1,4-OXAZINES, A NEW CLASS OF DOPAMINE AGONISTS

G. F. Lundell, P. Anderson, J. Hirshfield, 1985 .

EFFECT OF ANTIPHAGE SERUM ON THE VIRULENCE OF CORYNEBACTERIUM DIPHTHERIAE

P. B. Cowles, P. Anderson, 1958, Journal of bacteriology.

N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin -2-yl)-N- methyl-2-hydroxyethane-sulfonamide: a potent and selective alpha 2-adrenoceptor antagonist.

P. Anderson, V. J. Lotti, J. Huff, 1985, Journal of medicinal chemistry.

Cyclic amidine inhibitors of indolamine N-methyltransferase.

N. R. Hunter, P. Anderson, J. Rokach, 1979, Journal of medicinal chemistry.

Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.

P. Anderson, R. Gould, G. Hartman, 1995, Journal of Medicinal Chemistry.

Mechanism of sodium borohydride reduction of pyridinium ions. III. Formation of piperidines

P. Anderson, R. Lyle, W. E. Krueger, 1965 .

Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.

S Diamond, S S Ko, G L Trainor, 2000, Journal of medicinal chemistry.

Effects of non-peptidal CCK receptor antagonist (L-364,718) on pancreatic responses to cholecystokinin, gastrin, bombesin, and meat feeding in dogs.

P. Anderson, J. Konturek, S. Konturek, 1989, Gut.

The Reduction of Nitrogen Heterocycles with Complex Metal Hydrides

P. Anderson, R. Lyle, R. E. Lyle, 1966 .

Transannular reactions of dibenzo[a,d]cycloalkenes. 2. Synthesis of bridgehead substituted dibenzo[a,d]cycloalkenimines by a regiospecific transannular amine to olefin addition

B. E. Evans, K. Rittle, P. Anderson, 1979 .

Thermolysis and transannular reactions of 8,8-dichloro-2,3:5,6-dibenzobicyclo[5.1.0]octane derivatives

B. E. Evans, P. Anderson, M. Christy, 1978 .

A USEFUL SYNTHESIS OF 3-OXODIHYDROISOINDOLES

K. Shepard, P. Anderson, M. Christy, 1978 .

3'-Tetrahydrofuranylglycine as a Novel, Unnatural Amino Acid Surrogate for Asparagine in the Design of Inhibitors of the HIV Protease.

Arun K. Ghosh, P. Anderson, P. Darke, 1993, Journal of the American Chemical Society.

(+)- and (-)-3-Methoxycyproheptadine. A comparative evaluation of the antiserotonin, antihistaminic, anticholinergic, and orexigenic properties with cyproheptadine.

K. Rittle, P. Anderson, E. Engelhardt, 1977, Journal of medicinal chemistry.

Expanded-Spectrum Nonnucleoside Reverse Transcriptase Inhibitors Inhibit Clinically Relevant Mutant Variants of Human Immunodeficiency Virus Type 1

Ronald M. Klabe, L. Bacheler, P. Anderson, 1999, Antimicrobial Agents and Chemotherapy.

The mechanism of the reduction of pyridinium ions by sodium borohydride, II.

P. Anderson, R. Lyle, 1962 .

NMR and molecular modeling characterization of RGD containing peptides.

D. Veber, P. Anderson, R. Nutt, 2009, International journal of peptide and protein research.

Synthesis and evaluation of pyridyl analogs of L-735,524: Potent HIV-1 protease inhibitors

P. Anderson, Jiunn H. Lin, P. Darke, 1994 .

5‐Chloro‐3‐(phenylsulfonyl)indole‐2‐carboxamide: A Novel, Non‐ Nucleoside Inhibitor of HIV‐1 Reverse Transcriptase.

W. Greenlee, P. Anderson, T. Ciccarone, 1994 .

Oxidative deamination of aromatic 1,4-imines. A new synthesis of polynuclear aromatic hydrocarbons

P. Anderson, R. Allen, G. Gribble, 1976 .

Cycloalkylpiperazines as HIV-1 protease inhibitors: enhanced oral absorption

B. E. Evans, P. Anderson, Jiunn H. Lin, 1995 .

N-trimethylsilylpyrroles as dienes in the synthesis of 1,4-dihydronaphthalen-1,4-imines and isoindoles†

G. F. Lundell, P. Anderson, M. Christy, 1977 .

Transannular reactions of dibenzo[a,d]cycloalkenes. 3. Nature of the amine to olefin ring closure

B. E. Evans, P. Anderson, 1981 .

Stereoisomerism of cyproheptadine n-oxide.

P. Anderson, B. Arison, M. Christy, 1977, The Journal of organic chemistry.

Agents for the treatment of brain edema. 2. [(2,3,9,9a-Tetrahydro-3-oxo-9a-substituted-1H-fluoren-7-yl)oxy]+ ++alkanoi c acids and some of their analogues.

P. Anderson, H. Kimelberg, G. Stokker, 1986, Journal of medicinal chemistry.

Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-methyl-D-aspartate antagonists.

P. Anderson, J. Thies, W. J. Thompson, 1990, Journal of medicinal chemistry.

An application of N-trimethylsilylpyrroles as dienes in the Diels-Alder reaction. Synthesis of 1,4-dihydronaphthalen-1,4-imines

G. F. Lundell, P. Anderson, G. Ponticello, 1975 .

Synthesis of 9,10-dihydroanthracen-9,10-imines

K. Shepard, P. Anderson, G. Ponticello, 1979 .

Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors.

E A Emini, P. Anderson, P. Darke, 1991, Journal of medicinal chemistry.

HIV-1 protease inhibitors: synthesis and biological evaluation of glycopeptidemimetics.

W. M. Sanders, P. Anderson, P. Darke, 1993, Drug design and discovery.

Synthesis, assignment of absolute configuration, and receptor binding studies relevant to the neuroleptic activities of a series of chiral 3-substituted cyproheptadine atropisomers.

K. Rittle, P. Anderson, J. Springer, 1979, Journal of medicinal chemistry.

Non‐Peptide Fibrinogen Receptor Antagonists. Part 7. Design and Synthesis of a Potent, Orally Active Fibrinogen Receptor Antagonist.

P. Anderson, R. Gould, G. Hartman, 1995 .

Rapid stimulation of diacylglycerol production in Xenopus oocytes by microinjection of H-ras p21

P. Anderson, S. Aaronson, J. Moscat, 1987 .

Expression of the Aplysia californica rho gene in Escherichia coli: purification and characterization of its encoded p21 product

P. Anderson, J. Lacal, 1987, Molecular and cellular biology.

Generation of helper cell-independent cytotoxic T lymphocytes is dependent upon L3T4+ helper T cells.

P. Anderson, D. Roopenian, 1988, Journal of immunology.

Inhibitors of gastric acid secretion: 3,4-diamino-1,2,5-thiadiazole 1-oxides and 1,1-dioxides as urea equivalents in a series of histamine H2-receptor antagonists.

B. T. Phillips, P. Anderson, J. Hirshfield, 1982, Journal of medicinal chemistry.

Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma.

J J Baldwin, M. Murcko, P. Anderson, 1989, Journal of medicinal chemistry.

Novel conformationally constrained HIV-1 protease inhibitors: rational design, enzyme inhibition, and X-ray structure of an enzyme-inhibtor complex

P. Anderson, P. Darke, J. Huff, 1994 .

Conformationally constrained HIV-1 protease inhibitors

P. Anderson, P. Darke, J. Huff, 1994 .

Dopamine receptors labelled by PHNO

R D Larsen, P. Anderson, P. Seeman, 1993, Synapse.

Synthesis of 4-substituted 2H-naphth[1,2-b]-1,4-oxazines, a new class of dopamine agonists.

G. F. Lundell, P. Anderson, J. Hirshfield, 1984, Journal of medicinal chemistry.

A new class of D-heteroergolines: total synthesis and resolution of a 9-oxaergoline, 4,6,6a,8,9,10a-hexahydro-7-ethyl-7H-indolo[3,4-gh][1,4]benzoxazine

G. F. Lundell, P. Anderson, J. Baldwin, 1982 .

Substituted alkylpyridines as P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors: Improved pharmacokinetic profiles

P. Anderson, P. Darke, W. Schleif, 1995 .

Thiophene derivatives as extremely high affinity P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors

P. Anderson, P. Darke, W. Schleif, 1995 .

A new hydroxyethylamine class of HIV-1 protease inhibitors with high antiviral potency and oral bioavailability

P. Anderson, P. Darke, W. Schleif, 1994 .

Structure-activity studies and antiviral properties of hydroxyethylene transition state inhibitors of HIV-1 protease

P. Anderson, P. Darke, W. Schleif, 1992 .

Synthesis of (7R)-7H-indolo[3,4-gh][1,4]benzoxazines, a new class of D-heteroergolines with dopamine agonist activity.

G. F. Lundell, P. Anderson, J. Hirshfield, 1983, Journal of medicinal chemistry.

SYNTHESIS OF (7R)-7H-INDOLO(3,4-GH)(1,4)BENZOXAZINES, A NEW CLASS OF D-HETEROERGOLINES WITH DOPAMINE AGONIST ACTIVITY

G. F. Lundell, P. Anderson, J. Hirshfield, 1983 .

Transannular reactions of dibenzo[a,d]cycloalkenes. 1. Synthesis of dibenzo[a,d]cycloocten-6,12-imines and dibenzo[a,d]cyclohepten-5,10-imines

B. E. Evans, P. Anderson, M. Christy, 1979 .

A structurally unique, potent, and selective oxytocin antagonist derived from Streptomyces silvensis.

R. Freidinger, G. F. Lundell, P. Anderson, 1989, Endocrinology.

Synthesis of a Series of 4-(Arylethynyl)-6-chloro-4-cyclopropyl-3,4- dihydroquinazolin-2(1H)-ones as Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

W. M. Sanders, P. Anderson, W. Schleif, 1994 .

ADOPTIVE IMMUNITY IN IMMUNE‐DEFICIENT scid/scid MICE: I. Differential Requirements of Naive and Primed Lymphocytes for CD4+ T Cells During Rejection of Minor Histocompatibility Antigen‐Disparate Skin Grafts

P. Anderson, D. Roopenian, 1988, Transplantation.

Potent HIV Protease Inhibitors: The Development of Tetrahydrofuranylglycines as Novel P2‐Ligands and Pyrazine. Amides as P3‐Ligands.

Arun K. Ghosh, P. Anderson, P. Darke, 1993 .

3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors. Part 3.

W. F. Hoffman, P. Anderson, J. Hirshfield, 1986 .

3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors. Part 4. Side Chain Ester Derivatives of Mevinolin.

W. F. Hoffman, P. Anderson, A. Alberts, 1986 .